Immunicom

About:

Immunicom is a biotechnology company.

Top Investors: National Cancer Institute, National Institutes of Health

Description:

Immunicom is redefining the limits of immunotherapy through the development of innovative, non-pharmaceutical treatment approaches for cancer, inflammatory diseases, and autoimmune diseases.

Total Funding Amount:

$23.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2013-01-01

Founders:

Amir Jafri

Number of Employees:

11-50

Last Funding Date:

2022-06-14

IPO Status:

Private

Industries: